About a year ago, virtually every psychedelics company was focused on developing medical treatments that could be approved by regulators.In just a short period of time, a whole network of psychedelics startups focused on tech, delivery, and distribution have risen up to lay the groundwork for what might become aThere are still biotech companies working through clinical trials and talking with regulators to get medications on the market, and those startups are as popular as well.
We asked each VC to name one startup they had invested in and one they hadn't, and to explain why they picked those companies. We asked for private companies that hadn't yet announced plans to list on a public exchange. Three startups received more than one vote. Three VCs named Gilgamesh Pharmaceuticals, while Beckley Psytech and Delix Therapeutics received two votes each. Twelve other companies got one vote.of startups in the psychedelics space, based on how much funding they raised from investors. The 14 private companies on that list raised over $222 million in 2020, and four of the companies on that list were also named by VCs for this article.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: CNBC - 🏆 12. / 72 続きを読む »